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Abstract
The mammalian target of the rapamycin (mTOR) pathway, which drives cell proliferation, is frequently hyperactivated in a
variety of malignancies. Therefore, the inhibition of the mTOR pathway has been considered as an appropriate approach for
cancer therapy. In this study, we examined the roles of mTOR in the maintenance and differentiation of cancer stem-like
cells (CSCs), the conversion of conventional cancer cells to CSCs and continuous tumor growth in vivo. In H-Ras-transformed
mouse liver tumor cells, we found that pharmacological inhibition of mTOR with rapamycin greatly increased not only the
CD133+ populations both in vitro and in vivo but also the expression of stem cell-like genes. Enhancing mTOR activity by
over-expressing Rheb significantly decreased CD133 expression, whereas knockdown of the mTOR yielded an opposite
effect. In addition, mTOR inhibition severely blocked the differentiation of CD133+ to CD133- liver tumor cells. Strikingly,
single-cell culture experiments revealed that CD133- liver tumor cells were capable of converting to CD133+ cells and the
inhibition of mTOR signaling substantially promoted this conversion. In serial implantation of tumor xenografts in nude
BALB/c mice, the residual tumor cells that were exposed to rapamycin in vivo displayed higher CD133 expression and had
increased secondary tumorigenicity compared with the control group. Moreover, rapamycin treatment also enhanced the
level of stem cell-associated genes and CD133 expression in certain human liver tumor cell lines, such as Huh7, PLC/PRC/7
and Hep3B. The mTOR pathway is significantly involved in the generation and the differentiation of tumorigenic liver CSCs.
These results may be valuable for the design of more rational strategies to control clinical malignant HCC using mTOR
inhibitors.
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Introduction
Cancer stem-like cells (CSCs) are the most malignant subpop-
ulations in tumors because of their resistance to drug therapy and
association with poor outcomes. As in adult tissue-specific stem
cells, which have extensive self-renewal abilities that ensure the
continuous turnover of normal tissues, CSCs are required for
continuous tumor growth. Great progress has been made in the
identification and characterization of CSCs in several types of solid
tumors, such as those of the brain, breast, colon and liver [1–7]. In
addition, a few key signaling pathways, including Wnt/b-catenin,
AKT and TGF-b [8–13], have been implicated in the mainte-
nance of CSCs. However, the molecular events that preserve the
pool size and stem cell properties of CSCs by maintaining the
balance of proliferation, differentiation and self-renewal are still
poorly understood. Elucidating the mechanistic differences
between CSCs and conventional tumor cells may be valuable for
developing strategies for cancer therapy.
The mammalian target of rapamycin (mTOR) is an essential
serine/threonine kinase that regulates cell growth by controlling
protein synthesis, autophagy, endocytosis, and metabolism in
response to growth factors, nutrients, energy, and stress [14].
Increasing evidence indicates that the signaling pathways that
activate mTOR are frequently improperly regulated in most
human cancers [15–23]. Rapamycin, an inhibitor of mTOR, can
block tumor growth and inhibit tumor cell motility [24–26]. These
findings have promoted the clinical use of mTOR inhibitors for
cancer therapy. However, the use of mTOR inhibitors alone has
had limited clinical success [27,28]. The role of mTOR signaling
in the maintenance of CSCs has been addressed recently, but the
conclusions of these reports are controversial. In embryonic and
adult stem cells, mTOR hyperactivation resulted in the differen-
tiation and exhaustion of stem cells [29–32]. In the tumor
development, mTOR signaling has been shown to enhance the
survival of dormant tumor cells [33] and maintain the self-renewal
and tumorigenicity of glioblastoma stem-like cells [34] and breast
cancer stem-like cells [35]. In sharp contrast, mTOR inhibition by
rapamycin has been shown to significantly increase CD133
expression in gastrointestinal cancer cells via down-regulation of
HIF-1a [36]. However, there is a lack of in vivo data regarding the
changes in CSC maintenance and tumorigenicity in tumor cells
after transient exposure to rapamycin.
In this study, we examined the role of mTOR in the regulation
of CD133+ CSCs differentiation, the conversion of CD133-
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in vivo of mTOR-manipulated tumor cells. We found that mTOR
inhibition increased the CD133+ subpopulation in liver tumor
cells and potentiated the continuous growth of tumor cells in vivo
via preventing differentiation, biased insensitivity of CD133+
subpopulation to rapamycin-induced apoptosis, and increasing the
retrodifferentiation of CD133- to CD133+ cells.
Results
mTOR inhibition increases CD133+ subpopulations and
retain stemness properties in liver tumor cells
To elucidate whether mTOR is involved in the maintenance of
CSCs, H-Ras-transformed mouse liver tumor cells were employed
in the study. We found that the percentage of CD133+ cells, which
have been referred as a subpopulation containing CSCs [5,37,38],
was approximately 0.2 to 1% in H-Ras-transformed mouse liver
tumor cells (LPC-H) and 10 to 20% in the derived clone LPC-
H12, both of which expressed markers of live progenitor cells, and
the latter displayed much high potential of tumorigenicity (Figure
S1). To examine whether there was a significant difference in
mTOR activation between CD133- and CD133+ LPC-H12 cells,
we purified these two population by FASC sorting and found that
the CD133+ subsets exhibited lower activation of mTOR signaling
compared with CD133- cells, as indicated by the levels of
phosphorylated p70 S6 kinase (p-p70 S6) (Figure 1A). We next
examined whether mTOR inhibition could lead to a change in the
proportion of CD133+ LPCs. LPC-H and LPC-H12 cells were
treated with the mTOR inhibitor rapamycin and measured
CD133 expression by FACS. Intriguingly, the CD133+ fraction of
the cells treated with rapamycin was significantly greater than that
of the cells without treatment (Figure 1B and 1C). The influence of
rapamycin on the maintenance of CD133+ subpopulations was
dose- and time-dependent (Figure S2A and S2B). Expression of p-
p70 S6 was undetectable in cells after rapamycin treatment,
demonstrating the efficiency of rapamycin in eliminating mTOR
activity (Figure S2C). Notably, we found that the expression of
several stem cell-associated genes, such as Nanog, Klf4 and SOX2,
were increased significantly after treatment with rapamycin
(Figure 1D). To further identify the role of mTOR in the
CD133+ subpopulation, we knocked down mTOR expression in
LPC-H cells using the retrovirus expressing short hairpin RNA
(shRNA) (Figure 1E). Downregulation of mTOR expression via
mTOR shRNA-2 (mTOR-sh2) dramatically increased the
CD133+ fraction in cells in a time-dependent manner (Figure 1F
and 1G). Similar results were obtained in LPC-H12 cells (Figure
S2D).
In some human liver tumor cell lines, such as Hep3B, Huh7 and
PLC/PRF/5, the enhanced lever of CD133 expression after
treatment with rapamycin was also detected (Figure 2A–2D).
Similarly, the expression of stem cell-associated genes, including
Bmi1, Oct4 amd Nanog, were significantly increased in the
human liver tumor cell lines treated with rapamycin, even in
MHCC-97L cells that are no CD133 expression (Figure 2E).
Collectively, these data indicate that inhibition of mTOR could
enrich CSCs in both mouse and human liver tumor cells.
To investigate whether the disparities exist in the sensitivity to
rapamycin between CD133- and CD133+ cells, we directly
examined the effect of rapamycin on cell growth of the two
subsets among LPC-H12 cells. We found that rapamycin-
mediated inhibition in CD133- cells was greater than that in
CD133+ cells (Figure S3), indicating that a greater impairment of
the CD133- subset upon rapamycin treatment might partially
contribute to the enrichment of CD133+ cells.
mTOR activation by Rheb overexpression decreases the
CD133+ subpopulations
To test whether activation of mTOR signaling could decrease
the CD133+ subpopulations, Rheb, an activator of mTOR
signaling [39], was overexpressed in LPC-H and LPC-H12 cells
by retroviral infection. We found that Rheb expression signifi-
cantly enhanced mTOR activity, as determined by increased
phosphorylation of p70 S6 (Figure 3A). As expected, mTOR
activation resulted in significant exhaustion of the CD133+ subsets
(Figure 3B). A time-course analysis of CD133 expression by FACS
showed that Rheb overexpression gradually decreased the
percentage of CD133+ cells in LPC-H12 cells (from
19.2262.09% to 3.9460.86%), whereas cells infected with empty
retrovirus showed only a slight decrease in CD133 expression
(from 22.8562.17% to 16.9961.28%) (Figure 3C). Furthermore,
the expression of all detected stem cell-associated genes were
significantly reduced in Rheb-overexpressed cells (Figure 3D).
These results suggested that mTOR activation might enhance the
differentiation of CD133+ to CD133- liver tumor cells.
Single-cell culture experiments define a critical role for
mTOR in the conversion of CD133- to CD133+ liver tumor
cells
Previous studies have shown that conventional cancer cells can
be induced by certain events to express stem cell markers and
acquire properties of CSCs [40,41]. To address whether CD133-
cells can be converted to CD133+ tumor cells without adding
exogenous TGF-b, and if so, whether mTOR signaling is involved
in the process, we employed a single-cell long-term culture system
(Figure 4A). CD133- cells of LPC-H12 were FACS-sorted, and
each single cell was robotically plated into individual wells of 96-
well plates. After 10 days in 96-well plates, single-cell derived
clones were individually trypsinized and seeded into 24-well plates
for expansion. After 11 days, the cells were harvested for FACS
analysis of CD133 expression. Of significant interest, 46.7% of
colonies derived from single CD133- LPC-H12 cells expressed
CD133, and the percentage of CD133+ cells in the positive
colonies was approximately 1 to 7%. Notably, we found that
rapamycin treatment significantly increased both the formation of
CD133+ cell colonies and the percentage of CD133+ cells in
positive colonies (Figure 4B and 4C). Accordingly, using the same
protocol, downregulation of mTOR expression by shRNA in the
LPC-H12 cells dramatically increased the number of colonies that
contained CD133+ cells and the proportion of CD133+ cells in the
positive colonies (Figure 4D and 4E). Similar results were obtained
using LPC-H cells (data not shown). In agreement with the FACS
results, the level of CD133 mRNA in the single-cell-derived
colonies expressing mTOR-sh2 was significantly higher than that
in the colonies containing control shRNA (Figure 4F and 4G).
Repression of mTOR inhibits differentiation of CD133+
liver tumor cells
On the basis of recent findings that mTOR activity mediates the
exhaustion and differentiation of stem cells [29–31], we hypoth-
esized that the increase in the proportion of CD133+ cells in the
presence of rapamycin might be partially due to blockage of
differentiation of CD133+ cells. To test this hypothesis, we isolated
CD133+ cells from LPC-H12 by FACS sorting, and further
treated cells with rapamycin for 10 days. Strikingly, we found that
CD133+ expression declined substantially in the control group,
whereas the proportion of CD133+ cells in the rapamycin-treated
group was maintained (Figure 5A and 5B). Moreover, we sorted
CD133+ cells and seeded them for single-cell culture. At day 10 of
mTOR Regulates CD133+ Liver Tumor Cells
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single-cell-derived colonies were formed in the culture medium
with or without rapamycin, respectively. These colonies were then
transferred into 24-well plates. After one week of culture, we found
high levels of CD133+ cells in the colonies that had been treated
with rapamycin (Figure 5C). In agreement with these results, high
CD133 expression was associated with colonies derived from
single CD133+ cells with expression of shRNAs against mTOR
(Figure 5D). Collectively, these results illustrate that inhibition of
mTOR can maintain CD133+ subpopulations by suppressing the
differentiation of CD133+ cells.
mTOR inhibition maintains CD133+ subpopulations in
vivo and enhances re-propagation of Ras-dependent liver
tumors
To assess the maintenance of CD133+ subpopulations in tumor
cells in vivo by inhibition of mTOR, we injected LPC-H cells
expressing mTOR-sh2 or control shRNA into nude mice. After
two weeks, both types of cells resulted in tumor formation.
However, using FACS analysis to detect GFP+ tumor cells in the
xenotransplants on day 24, a high percentage of CD133+ cells
were preserved in tumors derived from LPC-H cells expressing
shRNA against mTOR (Figure 6A). No significant difference was
found in tumor size between the two types of cells (Figure 6B).
Increased proportion of CD133+ tumor cells was also found in the
tumor tissues after treatment of the tumor-bearing mice with
rapamycin for 10 days (Figure 6C).
The increase in CD133+ subsets induced by mTOR inhibition
led us to speculate that transient treatment with rapamycin might
result in the enhanced continuous growth of Ras-dependent mouse
liver tumors in vivo. We tested this hypothesis by taking advantage
of the secondary tumor xenograft model (Figure 7A). GFP+ LPC-
H cells were subcutaneously injected into nude mice. The nude
mice bearing xenografts were then treated with rapamycin or
control diluents beginning 3 weeks after tumor implantation. After
10 days of rapamycin treatment, tumor growth was significantly
reduced (Figure 7B and 7C). The tumor tissues were enzymatically
dissociated into single-cell suspensions, and CD133 expression was
analyzed in the GFP+ LPC-H cells. The significant increase in
CD133 expression in tumor cells from the first implantation after
rapamycin treatment was similar to the effect of downregulation of
mTOR in vitro. The tumor cells, harvested by FACS sorting of
GFP+ population, were then transplanted into the secondary
recipients. We found that as few as 2.5610
3 tumor cells with
rapamycin treatment were sufficient to initiate tumor develop-
ment, whereas up to 1610
5 tumor cells without rapamycin
treatment failed to initiate subcutaneous tumors in secondary
recipient mice (Figure 7D and 7E). Thus, mTOR inhibition by
rapamycin could block tumor growth from the first implantation
but enhance continuous growth of the secondary tumors derived
from H-Ras-transformed mouse liver cells.
Discussion
Aberrant activation of the mTOR pathway has been implicated
in the growth of various human cancers [42,43]. mTOR signaling
promotes cell proliferation, and, in the context of cancer
development, it is highly correlated with tumor expansion and
rate of tumor growth. Remarkably, several reports have
highlighted the critical importance of mTOR signaling in driving
differentiation of adult progenitor cells accompanied by rapid cell
expansion [29–32]. Recently, it has been established that the
preservation of small subpopulations of CSCs within tumors is
critical for tumors to assume malignant behavior and resistance to
therapy. To date, whether mTOR signaling is critically involved in
maintaining the balance between proliferation and differentiation
is still poorly defined. Because mTOR inhibitors have been
utilized for cancer therapy, and only modest or unremarkable
success has been achieved in some clinical trials [27,28], it is
urgent to investigate the long-term effects of transient mTOR
treatment on tumor re-emergence and malignant outcome. We
demonstrated here that targeted inhibition of mTOR significantly
enhanced the generation and maintenance of CD133+ subpop-
ulations and promoted secondary tumor re-propagation of H-Ras-
transformed mouse liver tumor cells in vivo.
CD133 is considered a universal marker of stem cells and CSCs
[44–46]. CD133+ tumor cells exhibit properties of CSCs in
human hepatocellular carcinomas and mouse liver cancer [47–
52]. In this study, we found that H-Ras-transformed mouse liver
tumor cells expressed the surface marker CD133. To our surprise,
by exploiting the difference in the status of mTOR activation
between CD133+ and CD133- populations, we found elevated
mTOR signaling in the CD133- subset. Although the mTOR
pathway has been reported to be important for the viability and
maintenance of breast and glioblastoma CSCs [34,35], inhibition
of mTOR with rapamycin in H-Ras-transformed mouse liver
cancer cells significantly increased the proportion of CD133+ cells
and retained the stemness properties. Using RNAi-mediated
knockdown of mTOR and overexpression of Rheb, an activator
of the mTOR kinase [53], we confirmed a critical role for mTOR
in exhaustion and differentiation of the CD133+ subsets.
Interestingly, these data are consistent with the notion that
elevated p70 S6 kinase activation induces differentiation of human
embryonic stem cells (hESCs) [30]. Furthermore, a previous study
has shown that persistent activation of mTOR in normal epithelial
stem cells results in exhaustion of these stem cells [29]. Notably,
mTOR pathway is also significantly important in the process of
cellular senescence in multiple human and rodent cells [54–56].
Rapamycin and MEK inhibitor that can target mTOR/S6
pathway, decelerate cellular senescence. Moreover, mTOR
inhibition attenuates cellular senescence but favors quiescence in
p53- arrested cells. These important findings are principally
supportive to our observation since the impaired capacity in
proliferation and the great potential to regain propagation
Figure 1. mTOR inhibition enriches CD133+ populations in oncogenic H-Ras-transformed mouse liver tumor cells. A mTOR signaling
was highly activated in CD133- subpopulations when compared with CD133+ compartments. Immunoblotting was performed for CD133,
phosphorylated p70 S6 (p-p70 S6), p70 S6, and a-tubulin as a loading control. B, C Enrichment of CD133+ cells in LPC-H and LPC-H12 cells after
rapamycin (RAPA) treatment (10 nM) for 3 days. Representative FACS profiles (B); summary bar graphs illustrate percentage of CD133+ cells as
means6S.E.M. of the results from three experiments (C). D Stem cell-associated gene expression measured via qPCR in LPC-H12 cells treated with or
without rapamycin (10 nM for 24 h). Real-time PCR experiments were conducted in triplicate and with GAPDH for expression normalization. E
Immunoblotting for mTOR, p-p70 S6, and p70 S6 confirmed mTOR knockdown by shRNAs. F, G Sustained increases of CD133 expression were
observed in LPC-H cells stably expressing shRNAs targeting mTOR. The means6S.E.M. of the percentages of CD133+ cells in LPC-H cells infected with
retrovirus expressing mTOR-shRNA (n=3) are shown in F. The magnitude of the change in percentage of CD133+ cells in LPC-H on days 13, 17 and 20
after infection with mTOR-sh1 and mTOR-sh2 containing retrovirus (means6S.E.M., n=3) (G).
doi:10.1371/journal.pone.0028405.g001
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Huh7 cells with treatment of rapamycin (100 nM) for 5 days. Representative FACS profiles (A); Percentages of CD133+ cells are presented as
means6S.E.M. (n=3) (B). C, D qPCR analysis shows enrichment of CD133 expression in human liver tumor cell lines after exposed to rapamycin
(100 nM). Relative expression of CD133 in Hep3B, Huh7, and PLC/PRF/5 with or without treatment of rapamycin for 48 h is shown in C. Sustained
increase of CD133 expression in Huh7 after treatment of rapamycin with 10 nM or 100 nM is illustrated in D. The sustained GAPDH was used as an
internal control. E qPCR ananlysis was performed for stem cell-associated genes in multiple human liver tumor cell lines. Cells without treatment of
rapamycin (100 nM) were defined as 1, and the relative expression of each gene in cells with treatment of rapamycin for 48 h was expressed as the
fold difference over this baseline. GAPDH was used as an internal control.
doi:10.1371/journal.pone.0028405.g002
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that the similar effect of rapamycin was also found in multiple
human liver tumor cell lines, such as Huh7, PLC/PRF/5, and
Hep3B, suggesting that, even it was able to inhibit growth of
tumor, rapamycin might enrich liver cancer stem-like cells in a
clinical setting.
Several studies have revealed that cellular stress (such as
hypoxia), cytokines (such as TGF-b), or activation of the mTOR
pathway are able to increase the expression of CSC surface
markers and phenotypes in certain bulk tumor cells [36,48,57,58],
indicating that cell-extrinsic environmental factors may reprogram
conventional tumor cells to cells with stem cell-like properties in
the course of cancer development. In the present study, using
single-cell culture experiments that can bring out conclusive
results, we unexpectedly revealed that CD133- liver tumor cells
were capable of converting to CD133+ cells, and blocking
intracellular mTOR activity with rapamycin or RNAi against
mTOR indeed promoted the conversion of CD133- to CD133+
cells. Notably, certain stem cell-associated genes are upregulated
by rapamycin prior to the increasing of CD133 expression in
LPCs, suggesting that these genes might function in the
rapamycin-mediated enrichment of CD133+ subpopulations.
Previous studies have shown that HIF-1a is a positive downstream
target of the mTOR signaling pathway [59]. In human glioma
cells, the activation of HIF-1a enhances CD133+ glioma-derived
cancer stem cell expansion by increasing self-renewal activity and
Figure 3. Activation of mTOR signaling by overexpression of Rheb inhibits the CD133 expression and stem cell-like potential. A
mTOR signaling was activated by overexpression of Rheb. Immunoblotting was performed for expression of p-p70 S6, p70 S6, and Rheb; a-tubulin
was used as a loading control. B, C Reduction in the pool size of CD133+ compartments following Rheb overexpression in LPC-H12 cells. LPC-H12
cells were infected with MSCV-Rheb or control MSCV retrovirus. At different time points, the cells were stained with mouse CD133-PE antibody to
identify CD133 expression. Representative FACS profiles of CD133 expression in LPC-H12 cells on day 12 after retroviral infection (B). Summary bar
graphs of the proportion of CD133+ cells in LPC-H12 after infection with MSCV-Rheb or control retrovirus (means6S.E.M., n=3) (C). D The magnitude
of change in stem cell-associated gene expression measured via qPCR in LPC-H12 cells with over-expression of Rheb. Real-time PCR experiments were
conducted in triplicate and with GAPDH for expression normalization.
doi:10.1371/journal.pone.0028405.g003
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single-cell culture of CD133- LPC-H12 cells. Single CD133- LPC-H12 cells were deposited by FACS into each well of 96-well plates with or without
rapamycin (10 nM). After expansion, the single-cell derived LPC-H12 cells were analyzed by FACS. Schematic diagram shows FACS isolation and
robotic plating of single CD133- cells into 96-well plates (A). Phase image of a single cell in one well after sorting (bottom). Bar=10 mm. The
percentages of the colonies containing CD133+ cells are shown in B (n=10 per group). The proportions of CD133+ cells in each colony are shown in
mTOR Regulates CD133+ Liver Tumor Cells
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HIF-1a and CD133 expression in the process of conversion
requires further investigation.
In human liver tumor cells, the induced CD133+ cells display
significant potential for tumorigenesis [48]. Indeed, we also found
that CD133 expression and certain stemness genes were
upregulated with the treatment of rapamycin. The relevant
significance of the regulation mediated by rapamycin on CSCs
maintenance was illustrated by the in vivo study, in which we
demonstrated that the tumor cells harvested from the first
implantation with treatment of rapamycin were significantly
higher in secondary tumorigenicity than those from the control,
as manifested by the increased CD133 expression. Notably, these
results are in agreement with the evidence derived from RNAi-
C. D-G Knockdown of mTOR expression enhanced the rate of conversion of CD133- to CD133+ cells. The percentages of CD133+ colonies derived
from single CD133- LPC-H12 cells infected with retrovirus containing mTOR-sh2 and control, respectively, are shown in D (n=12 per group). The
proportions of CD133+ cells in each colony are shown in E. The expression of CD133 mRNA in each clone examined by Real-time PCR experiments in
triplicate, and all samples were normalized to GAPDH expression (F). The result of RT-PCR is shown in G.
doi:10.1371/journal.pone.0028405.g004
Figure 5. The consequences of mTOR repression on the maintenance of CD133 expression. A, B Inhibition of mTOR signaling by
rapamycin severely blocked the rapid decrease of the CD133+ subsets over time in sorted CD133+ LPC-H12 cells. Representative FACS profiles of LPC-
H12 cells are shown in A. Changes of CD133 expression in LPC-H12 cells at days 3, 7, and 10 after cell sorting are shown in B. Data shown are the
means6S.E.M. of the results of three experiments. C Single-cell culture for analysis of the effect of rapamycin on the maintenance of the CD133+
subpopulations. The single CD133+ cell-derived colonies cultured in the media with rapamycin had more CD133+ cells than those in rapamycin-free
media. Single CD133+ LPC-H12 cells were sorted into 96-well plates and cultured with or without rapamycin (10 nM). Each symbol represents an
individual single-cell-derived colony; small horizontal lines indicate the means (n=8). D The percentage of CD133+ cells in each colony derived from
single CD133+ LPC-H12 stably expressing mTOR-sh2 was higher than that from single CD133+ LPC-H12 infected with control retrovirus. Data are
shown as the means6SD (n=8).
doi:10.1371/journal.pone.0028405.g005
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suggest that mTOR signaling is involved in regulation of the
balance of proliferation and differentiation of CSCs in Ras-
dependent tumorigenesis and that transient inhibition of mTOR
promotes tumor re-emergence via an increased CD133+ subpop-
ulation.
Taken together, our observations show that mTOR inhibition
enriches CD133+ subpopulations. This enrichment is most likely
achieved through blocking differentiation of the CD133+
subpopulations, enhancing apoptosis in the CD133- subsets, and
triggering the conversion of CD133- to CD133+ cells. The
maintenance of CD133+ cells in vivo by rapamycin leads to high
continuous tumorigenic potential. Therefore, therapeutic design
strategies should consider the possibility that complex regulatory
events in CSC generation may be triggered by mTOR inhibition.
Materials and Methods
Ethics statement
All animal experiments were conducted in accordance with
protocols approved by the Shanghai Medical Experimental
Animal Care Commission (approval ID. ShCI-11-020).
Cell culture
Isolation, culturing and retroviral infection of purified p53-/- mouse
fetal liver progenitor cells were performed as described by Zender et
al. [61,62]. Retroviruses were based on MSCV-IRES-GFP vectors
containing cDNAs encoding H-Ras and used for infection of the
purified cells. H-Ras-transformed mouse liver tumor cells were
cultured in a maintenance medium containing 1:1 DMEM:F12
(GIBCO, Grand Island, NY) with 10% fetal bovine serum (GIBCO)
Figure 6. Inhibition of mTOR increases the CD133+ cells in vivo.AThe percentage of CD133+ cells in GFP+ cells harvested from xenograft
tumors with mTOR-sh2 expression was higher than that from control ones. LPC-H cells with GFP infected with control or mTOR-sh2 retroviral vector
were subcutaneously implanted into nude BALB/c mice (n=3 per group). The animals were euthanized on day 24. The percentage of CD133+ cells in
GFP+ tumor cells with expression of mTOR shRNA and control shRNA are shown as the means6SD (n=3). B There was no significant effect of
knockdown mTOR on tumor growth of LPC-H cells in vivo. Differences in tumor size in mm
3 between control and mTOR-knockdown groups are
reported as means6SD. C The xenografts of LPC-H cells contained a high proportion of CD133+ cells in the mice after rapamycin treatment for 10
days. FACS analysis profile (left). Percentages of CD133+ cells in LPC-H cells in vivo are presented as means6SD (n=5) (right).
doi:10.1371/journal.pone.0028405.g006
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injected into nude BALB/c mice (n=5 per group). After 3 weeks of tumor growth, the animals were treated with rapamycin (1.5 mg/kg/day) or
diluents for 10 days, and then euthanized. Tumor cells were dissociated, and GFP+ tumor cells were then implanted into secondary recipients. B, C
Subcutaneous tumors grew more slowly in nude BALB/c mice after treatment with rapamycin than did tumors without rapamycin treatment. Original
magnification (B) and growth curve of xenograft tumors in nude mice (C). D Continuous tumorigenesis of LPC-H cells with exposure to rapamycin in
vivo was more efficient than that without rapamycin treatment. The tumor cells from nude BALB/c mice with or without treatment with rapamycin
(1.5 mg/kg/day) for 10 days were secondarily implanted into the right or left flanks of the mice, respectively. Arrows indicate tumor formation
(2.5610
3 GFP+ tumor cells implanted). E The secondary tumor-initiating ability of LPC-H cells treated with or without rapamycin in the nude BALB/c
xenograft transplant model. Tumor initiation was monitored for 4 wk after implantation.
doi:10.1371/journal.pone.0028405.g007
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27 M; Sigma-
Aldrich, St. Louis, MO), nicotinic acid (0.01 M; Sigma-Aldrich), 2-
mercaptoethanol (50 mM; Sigma-Aldrich), 16 ITS liquid media
supplement (Sigma-Aldrich), EGF (20 ng/ml; R&D Systems, Min-
n e a p o l i s ,M N ) ,H G F( 5 0 n g / m l ;R & DS y s t e m s ) ,a n dp e n i c i l l i n /
streptomycin (1% [v/v]; GIBCO). For treatment studies, cells were
plated and grown overnight in 1:1 DMEM:F12 with 10% fetal bovine
serum and penicillin/streptomycin (1% [vol/vol]). The medium was
then replaced the following morning with medium containing
rapamycin (Cell Signaling Technology, Beverly, MA) at concentra-
tions of 0 to 100 nM. To assess the inhibition of mTOR by
rapamycin,cells were treated with rapamycin (10 nM) for 24 h. These
cells were lysed for immunoblot analysis.
Human liver tumor cell lines, Huh7 (purchased from Riken Cell
Bank, Tsukuba Science City, Japan), MHCC-97L (purchased
from Liver Cancer Institute, Fudan University, Shanghai), Hep3B
and PLC/PRF/5 (purchased from American Type Culture
Collection, Manassas, VA) were maintained in DMEM with high
glucose (GIBCO) supplemented with 10% fetal bovine serum and
penicillin/streptomycin (1% [vol/vol]).
Retroviral transfection
A Rheb cDNA was Flag-tagged and cloned into the retroviral
expression vector MSCV (MSCV-Rheb). Recombinant retroviral
particles were generated from the Phoenix packaging cell line and
harvested 2 consecutive times for infection. Transfected cells were
pooled for further analysis after selection with 10 mg/ml of
puromycin (Sigma-Aldrich) for 1 week and then with 5 mg/ml for
additional 1–2 weeks. Short-hairpin RNAs targeting mTOR
(mTOR-sh1 and mTOR-sh2), based on mTOR coding sequences
5’-AAGAATGTTGACCAATGCT-3’ and 5’-TGATGGACA-
CAAATACCAA-3’ respectively, were expressed from the LTR
promoter of MSCV retroviruses.
Immunoblotting
Cell lysates were prepared with RIPA lysis buffer (Beyotime,
Nantong, China) with Protease Inhibitor Cocktail and PhosSTOP
Phosphatase Inhibitor Cocktail (Roche, Monza, IT) added.
Specific antibodies were used for analysis: anti-phospho-mTOR
(Ser2448), anti-mTOR, anti-phospho-p70 S6 kinase (Thr389),
anti-p70 S6 kinase (all from Cell Signaling Technology); anti-Flag
(Sigma); and anti-a-tubulin (Santa Cruz Biotechnology, Santa
Cruz, CA). Images were obtained with the ChemiDoc
TM XRS
system (Bio-Rad Laboratories, Hercules, CA).
RNA extraction, reverse-transcription, and RT-qPCR
Total RNA was extracted from cultured cells with RNAiso
Reagent (TaKaRa, Dalian, China) and converted to cDNA using
the PrimeScript
TM RT reagent kit (TaKaRa) according to the
manufacturer’s protocol. Gene expression analysis was determined
using primers for CD133, AFP, albumin (Alb), cytokeratin 19 (CK19),
and GAPDH, as listed in Table S1. For detection of CD133
expression, relative quantitative PCR (qPCR) was performed on a
7300 Real-Time PCR System (Applied Biosystems, Foster City,
CA) using Premix Ex TaqTM (TaKaRa). Quantitative real-time
PCR was performed using SYBR green mix from TaKaRa for
Bmi1, Klf4, Nanog, Oct4, and Sox2. All samples were normalized to
the level of GAPDH. The primers are listed in Table S1.
Fluorescence-activated cell sorting and single-cell
analysis
Cells were dissociated and resuspended in PBS containing 0.5%
BSA. Flow cytometry was performed with PE-conjugated anti-
mouse CD133 antibody (eBioscience, San Diego, CA) or PE-
conjugated anti-human CD133 antibody (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) incubated at 4uC for 30 min. Rat
IgG1/k antibody conjugated to phycoerythrin was used as an
isotype control. Preincubation with 7-AAD (Sigma-Aldrich) was
used to exclude dead cells.
For cell sorting, samples were stained with PE-conjugated
anti-mouse CD133 antibody and analyzed using a MoFlo XDP
(Beckman Coulter, Fullerton, CA) with rat IgG1/k antibody
conjugated to phycoerythrin as isotype controls. Isolated
CD133- or CD133+ cells were plated in 6-well plates. For
single-cell experiments, single CD133- or CD133+ cells were
stringently gated, isolated using a FACSVantage set for Single
Cell Purity, and robotically plated into a 96-well plate with
150 ml medium/well. After 24 h, an additional 50 mlm e d i u m
with or without rapamycin was added to each well. After 1–2
weeks in culture, robust single-cell-derived colonies that filled
more than 50% of the well area were transferred into 24-well
plates for expansion.
Tumor cell preparation
Tumor tissue was mechanically cut into small pieces with sterile
scalpel blades, then enzymatically dissociated for 1 h with a
mixture of collagenase type I (0.05 mg/ml; Sigma-Aldrich),
collagenase type IV (0.05 mg/ml; Sigma-Aldrich), hyaluronidase
(0.025 mg/ml; Sigma-Aldrich), and DNase I (0.01 mg/ml; Roche)
at 37uC and shaken repeatedly. The dissociated sample was then
filtered (70-mm pore size) and washed with PBS. Cells were then
injected into nude BALB/c mice for secondary tumor propagation
or stained with mouse CD133-PE antibody for assessing CD133
expression using a FACSCalibur flow cytometer (BD Biosciences,
San Jose, CA).
Subcutaneous implantation into nude BALB/c mice and
rapamycin treatment
H-Ras-transformed mouse liver tumor cells (1610
6)w e r e
suspended in 100 ml PBS and injected subcutaneously into male
nude BALB/c mice (5 to 6 weeks of age). Tumor size was serially
measured using calipers. Tumor volume was estimated using the
following formula: (w16w26w2)/2, where w1 represents the length
and w2 represents the width of the tumor. In some experiments,
rapamycin (LC Laboratories, Woburn, MA) was reconstituted in
absolute ethanol at 10 mg/ml and diluted in 5% PEG-400
(Sigma-Aldrich) and 5% Tween-80 (Sigma-Aldrich) for treatment
of mice. Each treatment group consisted of 4 or 5 animals. Nude
mice bearing xenografts received 1.5 mg/kg rapamycin by i.p.
injection daily starting 3 weeks after tumor transplantation.
Control animals bearing tumors were treated with diluent at
equivalent doses and schedules to the experimental animals.
Tumors were removed and injected into secondary recipients by
limiting dilution experiments.
Cell viability assay
A total of 500 cells/well were plated in 96-well plates. After
24 h, rapamycin (10 nM) was added to the media. Cell viability
was performed daily by adding 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) (Sigma-Aldrich) to each
well and measuring the absorbance at 540 nm.
Apoptosis assay
For quantification of apoptosis, Pharmingen
TM PE Aneexin V
Apoptosis Detection Kit (BD Biosciences) was performed accord-
ing to the manufacturer’s instructions.
mTOR Regulates CD133+ Liver Tumor Cells
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28405Statistical analysis
Statistical analyses were performed using SPSS 11.5.0. A paired,
two-tailed Student’s t test was used to determine the significance
between two groups. A p value less than 0.05 was considered
statistically significant.
Supporting Information
Figure S1 Progenitor cell phenotype and tumorigenesis
in LPC-H and LPC-H12 cells. A RT-PCR analysis revealed
that both hepatocyte and cholangiocyte markers were expressed in
LPC-H and LPC-H12 cells. B The tumorigenic potential of LPC-
H and LPC-H12 cells. The tumor-forming ability of LPC-H12
cells was higher than that of LPC-H cells.
(TIF)
Figure S2 Inhibition of mTOR up-regulates the propor-
tion of CD133+ cells. A Flow cytometer analysis of CD133
expression in LPC-H on days 3 and 6 after rapamycin treatment
of different concentrations. B The bar graphs illustrate the
sustained increase in CD133+ cells in LPC-H12. Data shown are
the means6S.E.M. of the results from three experiments. C
mTOR signaling was efficiently inhibited by rapamycin. Phos-
phorylated mTOR (p-mTOR), mTOR, p-p70 S6, and p70 S6
were measured by immunoblot, and a-tubulin was used as a
loading control. D Sustained increases of CD133 expression were
observed in LPC-H12 cells stably expressing shRNAs targeting
mTOR. The means6S.E.M. of the percentages of CD133+ cells
in LPC-H12 cells infected with retrovirus expressing mTOR-
shRNA (n=3) are shown.
(TIF)
Figure S3 Selected sensitivity to rapamycin existed
between CD133- and CD133+ cells. A Rapamycin induced
apoptosis in the CD133- and CD133+ compartments of LPC-H12
cells. B Cell proliferation in CD133- and CD133+ subsets in LPC-
H12 cells after treatment with rapamycin (10 nM) for 5 days. Cell
viability was measured by MTT.
(TIF)
Table S1 List of the primers for RT-PCR.
(DOC)
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